SCHEMBL16712908

SCHEMBL16712908

CN1CCC(Oc2ccc(-c3cccc(NC(=O)c4ccc5ccccc5c4)c3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 6/20 0.54
WNT1 P04628 4/20 0.52
GSK3B P49841 4/20 0.52
DYRK1A Q13627 4/20 0.52
CLK2 P49760 1/20 0.52
CLK3 P49761 1/20 0.52
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
ADORA3 P0DMS8 1/20 0.51
PLG P00747 3/20 0.50
PLAT P00750 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
F2 P00734 1/20 0.50
KLKB1 P03952 1/20 0.50
PRSS1 P07477 1/20 0.50
KDR P35968 2/20 0.49
LCK P06239 1/20 0.49
MAPK14 Q16539 1/20 0.49
DGAT1 O75907 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16701562 0.92 RAB9A (0.61) PLAUWNT1GSK3BDYRK1ACLK2
SCHEMBL16701865 0.90 ADORA3 (0.58) WNT1GSK3BDYRK1ACLK2CLK3
SCHEMBL23969974 0.89 DYRK1A (0.49) WNT1GSK3BDYRK1ACLK2CLK3
SCHEMBL16701543 0.88 ADORA3 (0.65) PLAUWNT1GSK3BDYRK1ACLK2
SCHEMBL16701480 0.88 SMN1; SMN2 (0.55) WNT1GSK3BDYRK1ACLK2CLK3
SCHEMBL16712912 0.87 UTS2R (0.51) WNT1GSK3BDYRK1ACLK2CLK3
SCHEMBL16702061 0.87 SMN1; SMN2 (0.54) WNT1GSK3BDYRK1ACLK2CLK3
SCHEMBL23969988 0.87 ADORA3 (0.52) WNT1GSK3BDYRK1ACLK2CLK3
SCHEMBL16702115 0.87 WNT1 (0.53) WNT1GSK3BDYRK1ACLK2CLK3
SCHEMBL16701930 0.87 SMN1; SMN2 (0.54) WNT1GSK3BDYRK1ACLK2CLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3066072-B1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIV KANSAS (US) 2021-11-03 EP disclosed
US-10689344-B2 Biphenylamide derivative Hsp90 inhibitors UNIVERSITY OF KANSAS (US) 2020-06-23 US disclosed
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIVERSITY OF KANSAS (US) 2016-09-22 US disclosed
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIVERSITY OF KANSAS (US) 2016-09-22 US disclosed
WO-2015070091-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS THE UNIVERSITY OF KANSAS (US) 2015-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689344-B2 Biphenylamide derivative Hsp90 inhibitors HSP90AB1, HSP90AA1, HSP90AB2P PLAU 4810/4885WNT1 2862/4885GSK3B 1960/4885
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P PLAU 4810/4885WNT1 2862/4885GSK3B 1960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.